Scancell Final Results for the Year Ended 30 April 2013
7/9/2013 8:51:04 AM
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
July 9, 2013 -- Scancell Holdings plc, („Scancell? or the „Company?) the developer of novel immunotherapies for the
treatment of cancer , announces results for the year ended 30 April 2013.
Highlights during the period:
Successful completion of Part 1 of the SCIB1 Phase 1/2 clinical trial
Part 2 of the SCIB1 Phase 1/2 clinical trial fully recruited and on track for completion by the end of
Additional 8mg dose study underway, also expected to be completed by the end of 2013
Development of new Moditope™ platform
Strengthened IP with patents awarded in the US and Japan for protein Immunobody® technology
Peter Allen appointed as a Director
Post period highlights:
Placing and Open offer up to £6.5 million (announced today)
Richard Goodfellow, Joint CEO of Scancell, said:
“We have made excellent progress this year with the successful completion of Part 1 of our Phase 1/2
clinical trial for SCIB1, Part 2 remains on track and our additional 8mg dose study has also commenced. We
are delighted that four of the six patients from the 2mg and 4mg dose groups are still alive with one patient
remaining disease free two years after initiating treatment.
“We believe our innovative Moditope™ platform has the potential to generate a new class of powerful cancer
immunotherapy treatments. We are putting funding in place to identify a lead from this programme and
develop it through to the point at which we have secured regulatory approval to start clinical trials, a key
value inflexion point. We are confident that such targeted further development of the Immunobody® and
Moditope™ platforms will both strengthen Scancell?s position as a leading immunotherapy player and allow it
to realise an enhanced value for shareholders.”
For Further Information:
Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
+ 44 (0) 74 2323 0 497
Cenkos Securities: +44 (0) 20 7397 8900
FTI Consulting +44 (0) 20 7831 3113
I am pleased to report on the company?s results for the year ended 30th April 2013
Good progress has been made with Part 2 of the Phase 1/2 clinical trial on SCIB1, with the final patient
recruited in January 2013. Recruitment of additional patients for the 8mg dose cohort, which is running in
parallel with Part 2 of the Phase 1/2 study, has also commenced.
Following a review, the Board has decided that additional value can be delivered to shareholders by the
further development of the new platform technology, Moditope . Whilst currently at an early stage, we
believe that the potential of this novel immunotherapy platform could be considerable and as a result plan to
identify a lead product to take into pre-clinical and clinical development by the third quarter 2014. Scancell
has provisionally selected triple-negative breast cancer (TNBC), ovarian and endometrial cancers as the
initial target indications for the first clinical study which is scheduled to start in 2016. The Company has
today announced a Placing and Open Offer of up to £6.5million. These additional funds will enable the
Company to commence work on the pre-clinical development of the first Moditope™ immunotherapy product
and will also give the Company the opportunity to strengthen the clinical data on the 8mg dose of SCIB1,
both in terms of number of patients treated and the duration of treatment.
Profit and Loss
The Group has made a loss for the year from continuing operations of £1,901,944 (2012: loss:
(£1,930,064)). The loss for the year was £1,901,944 (2012: profit £557,058).
The increase in development costs in the year reflects the additional costs incurred in the manufacture of the
8mg dose for use in the clinical trials.
The reduced administrative expenses are largely due to the reduction in the charge for share options which
has occurred as all of the share options have now reached the end of their vesting period.
At the end of the year the Group cash balances amounted to £1,491,320 (2012: £3,529,007). This reduction
in cash is attributable to the loss for the year.
The Group?s net assets at 30th April 2013 amounted to £5,092,145 (2012: £6,971,337).
The ImmunoBody® Technology Platform
Scancell?s mission is to develop medications that fight cancer by spurring the body?s immune system. This is
a form of treatment that many cancer specialists believe may hold the key to keeping a patient permanently
disease-free. Unlike traditional therapies that attack a cancer directly, immunotherapy uses the body?s own
internal defences to ward off the disease, with the ultimate hope of building up long term resistance to the
Scancell?s ImmunoBody® vaccines generate potent killer T-cells that target and eliminate tumours. Each
ImmunoBody vaccine can be designed to target a particular cancer in a highly specific manner, offering the
potential for enhanced efficacy and safety compared with more conventional approaches.
The manipulation and enhancement of human immune systems is also relevant to the treatment of other
diseases such as chronic infectious disease. Although Scancell does not intend to venture outside the
oncology arena itself, the Company intends to license ImmunoBody® to companies working in other
SCIB1 melanoma vaccine
In December 2012, the Company announced preliminary results from Part 1 of the Phase 1/2 clinical trial of
its DNA ImmunoBody® vaccine in patients with Stage III/IV malignant melanoma. Of the six patients
allocated to the 2mg and 4mg dose cohorts and of those who received at least four doses of SCIB1, four are
still alive and four showed a vaccine induced T cell response to treatment. The vaccine produced very few
side effects, none of which were serious. These encouraging results provide the first evidence that
Scancell?s ImmunoBody® vaccine approach is producing an immune response in cancer patients which
might also be associated with clinical benefit.
The first part of this Phase 1/2 clinical trial was conducted in five UK centres in eleven patients, ten with
stage IV and one with stage III malignant melanoma. Patients were given five doses of 0.4mg, 2mg or 4mg
of SCIB1, delivered by Ichor Medical Systems? TriGrid™ electroporation delivery device, over a period of six
months. One patient in the 0.4mg dose group and one in the 4mg dose group who received only a single
dose of SCIB1 were withdrawn from the study due to progressive disease shortly after study entry and were
replaced to ensure that at least three patients in each dose cohort could be fully evaluated for immune
response. During the course of the study regulatory approval was granted to increase the SCIB1 dose from
2mg to 4mg in patients in the 2mg cohort, if the vaccine was well tolerated. Two patients in this group
received two 4mg doses of SCIB1 and one patient received a single 4mg dose.
Four of the six patients in the 2mg and 4mg cohorts who received at least 4 doses of SCIB1 are still alive
and one remains disease-free two years after starting treatment. All four patients in the 0.4mg dose group
have now died.
One patient in the 4mg dose group had a long history of metastatic disease and multiple tumour lesions
present at the start of treatment (including several in her lungs), all of which decreased in size or
disappeared completely following six months of treatment with SCIB1 except for one abdominal tumour
nodule which increased in size and which has been resected. This "differential response" pattern is typical of
immunotherapeutic agents and is the first signal that SCIB1 may be having an impact on the course of the
disease as well as inducing an immune response. Additional studies have suggested that this abdominal
tumour may have been largely composed of cells that do not express gp100 and which may therefore not be
a suitable target for SCIB1 (which targets tumours that express either gp100 or TRP-2). This finding
provides further circumstantial evidence that SCIB1 is successfully targeting tumours that express one of
more of these antigens. A second abdominal tumour has since been detected.
One patient on SCIB1 remains disease-free two years after treatment started. This patient (in the 2mg
cohort but who also received two 4mg doses at three and six months after the start of dosing) was entered
into the study after all recurrent tumour had been resected and remains disease-free 24 months after first
dosing and 30 months after the last tumour excision.
All three patients in the 2mg/4mg dose cohort and one patient in the 4mg dose cohort produced an
increased immune response to the melanoma specific epitopes in SCIB1. The two patients in the 4mg group
who did not show an increased immune response to treatment had a strong pre-existing immune response
to the target antigens at study entry which could not be increased with SCIB1. Only one of the patients in
the lowest dose group showed any immune response to treatment.
The first patient was recruited to Part 2 of the Phase 1/2 clinical trial in May 2012 and the final patient started
treatment in January 2013. As expected, the recruitment of patients in the second part of the trial proceeded
faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design
requiring sequential dose escalation, and there were more patients available with earlier stage disease. Part
2 of the study is on track to be completed by the end of 2013.
GTAC and MHRA have also given their approval to increase the maximum treatment period from six months
up to a further five years in these clinical trials. The continuation option will be available for patients with
stable disease. This approval provides our investigators with the opportunity to continue dosing patients
whose disease has not progressed whilst receiving the SCIB1 vaccine and will allow the Company to gather
longer term data on late stage melanoma patients for whom the prognosis is poor. Four patients are
currently receiving long term treatment with SCIB1.
In view of the positive clinical results and minimal side effects seen with the 4mg dose, the Company is
currently evaluating an 8mg dose in 3-6 patients with evaluable disease.
This additional cohort will permit an assessment of the safety and immunogenicity of an increased dose of
SCIB1 in addition to the effect of this higher dose on tumour burden. The 8mg cohort is being evaluated in
parallel with the second part of the Phase 1/2 study which is primarily designed to assess the effect of the
4mg dose on immune response in patients who have had all tumours removed prior to treatment. Three
patients have been recruited to the 8mg dose cohort to date. Provided that the 8mg dose is well tolerated,
the Company plans to seek approval to recruit an additional 10 patients with evaluable disease to strengthen
the data set on the 8mg dose prior to closing the SCIB1 Phase1/2 programme.
In a further important step in the development and commercialisation of SCIB1, Scancell has been granted a
number of patents during the year. The granting of a composition of matter patent in Europe for SCIB1
protects the unique composition of the vaccine until March 2028. The Company has also had protein
ImmunoBody® vaccine patents approved in the United States and Japan. These patents will further
strengthen Scancell?s IP position and are an important step in the development and commercialisation of the
ImmunoBody® platform. The DNA ImmunoBody® patent is expected to be granted in its first jurisdiction in
the second half of 2013.
The Moditope Technology Platform
On 15 August 2012, the Company announced the development of a new platform technology, Moditope ,
which stimulates the production of killer CD4 T cells with powerful anti-tumour activity. CD4 responses to
cancer associated antigens have been notoriously difficult to generate whether presented as peptides,
proteins or DNA, yet are vital for effective anti-tumour immunity. Scancell has identified and patented a
series of modified epitopes that overcome this limitation. Scancell?s Moditope technology produces killer
CD4 T cells that destroy tumours without toxicity.
The discovery of the highly innovative Moditope platform opens up a new approach to the development of
cancer immunotherapy treatment. Whilst currently at an early stage, we believe that the potential of this
novel immunotherapy platform could be considerable and, as a result, plan to identify a lead product to take
into clinical trials as soon as possible. Scancell has provisionally selected triple-negative breast cancer
(TNBC), ovarian and endometrial cancers as the initial target indications for the first clinical study.
The patent describing the Moditope™ platform was filed in August 2012 and is due to be published in August
2013 after which further details about the technology platform and development plan will be presented to
The proposed funding, mentioned below will provide the Company with the financial resources to take
Moditope™ to the initial stage of clinical testing which will include the manufacture of material for toxicology,
stability and clinical trials, a pre-clinical package, a defined regulatory strategy and clinical plan.
Scancell has today announced a placing of £4.5 million together with an open offer to raise up to £2.0
These additional funds will enable the Company to commence work on the pre-clinical development of the
first Moditope™ immunotherapy product and will provide working capital for the completion of the SCIB1
Board of Directors
Nigel Evans resigned as a Director and Company Secretary on 11 December 2012 and Mike Rippon
resigned as a Director on 27 February 2013. Both have given unstinting service and made an important
contribution to Scancell over many years and I wish them well in their retirement.
Peter Allen was appointed as a Director on 1 April, 2013. A chartered accountant by profession he has held
key senior positions in a number of companies in the life sciences industry, playing a significant role in their
development. Peter?s strategic oversight and broad experience with innovative life science companies will
be invaluable to Scancell.
The Board recognises that the progress made over the year would not have been possible without the
dedication and determination of all our staff and, on behalf of the directors, I offer our warmest thanks to
The Company is entering an important juncture in its development. We are awaiting the results from Part 2
of our Phase I/II trial on SCIB1, expected at the end of this calendar year, together with the results of the
8mg dose which is being tested in parallel with Part 2 of the clinical trials. In addition, significant
development work will be commencing on the Moditope platform.
The board of directors is firmly committed to a trade sale and believes that successful results from the clinical
trials for SCIB1 together with the development of the Moditope platform will make Scancell an even more
attractive acquisition opportunity to Pharmaceutical companies and provide a further significant boost to
Help employers find you! Check out all the jobs and post your resume.
comments powered by